Stocksigma LogoStocksigma Logo

Hikal Reports Q2 FY27 Earnings with Strong Revenue and Operational Recovery

Hikal reported consolidated revenue of ₹434 crore for Q2 FY27, up 36% YoY and 8% QoQ, driven by recovery in its API portfolio and sustained CDMO execution

Hikal Reports Q2 FY27 Earnings with Strong Revenue and Operational Recovery

Hikal Ltd · Press Release · 03 Nov 2026, 9:27 pm

Hikal Reports Q2 FY27 Earnings with Strong Revenue and Operational Recovery Hikal reported consolidated revenue of ₹434 crore for Q2 FY27, up 36% YoY and 8% QoQ, driven by recovery in its API portfolio and sustained CDMO execution. Pharmaceuticals revenue rose 47% YoY to ₹278 crore, while Crop Protection grew 21% YoY to ₹156 crore. EBITDA jumped to ₹45 crore with a 10.3% margin, narrowing net loss to ₹6 crore from ₹35 crore YoY. The company signed a multi-year European agrochemical CDMO contract, secured Swissmedic approval, and reiterated mid-teens revenue growth guidance for FY27.

Original exchange filing (PDF)

More announcements from Hikal Ltd

All Hikal Ltd announcements